We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





New One-Minute COVID-19 Test Detects Antibodies from Single Drop of Blood

By LabMedica International staff writers
Posted on 30 May 2020
A one-minute test for antibodies to SARS-CoV-2 is currently being developed based on an innovative testing technology that detects antibodies within one minute from a single drop of blood.

The test is being developed on bioLytical Laboratories Inc.’s (Richmond, BC, Canada) proprietary INSTI platform. More...
bioLytical will receive advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop the one-minute test for antibodies to SARS-CoV-2.

INSTI is made in Canada and known for its fast, easy-to-use, and accurate serological tests. As an antibody test, an INSTI test for SARS-CoV-2 can be an important part of the testing strategy in Canada and around the world. By detecting antibodies to COVID-19 in a single drop of blood, INSTI does not require additional materials such as swabs. Along with the test device, all materials required to perform the test are provided together in one small pouch; leading this testing platform to become known as “a lab in a pouch.”

The INSTI SARS-CoV-2 test development project is funded by NRC IRAP and aims to accelerate research and development for solutions to address COVID-19 related gaps and challenges identified by health experts.

Related Links:
bioLytical Laboratories Inc.


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Hematology Consumables
Bioblood Devices
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical Abstract (Ziegler, AG., Rewers, M.J., Achenbach, P. et al. Diabetologia (2026). https://doi.org/10.1007/s00125-026-06841-z)

International Consensus Guidance Outlines General Population Screening for Early-Stage Type 1 Diabetes

Type 1 diabetes (T1D) is an autoimmune disease that can develop in childhood or adulthood and affects an estimated 9.5 million people worldwide. Its complications range from acute diabetic ketoacidosis... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures

Hospitals face persistent pressure to improve diagnostic accuracy while reducing unnecessary testing and costs. Misordered or overused assays can complicate infection metrics, trigger penalties, and strain... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.